Takeda Pharmaceutical Company Limited
SUBCUTANEOUS ADMINISTRATION OF ANTI-CD38 ANTIBODIES
Last updated:
Abstract:
Methods of administering isolated anti-CD38 antibodies at low dosages subcutaneously are disclosed. The methods provide an effective treatment for autoimmune diseases and cancers, including hematologic diseases. Also disclosed are unit dosage forms for the anti-CD38 antibodies.
Status:
Application
Type:
Utility
Filling date:
14 Jan 2019
Issue date:
16 Dec 2021